NCT00333255已完成3 期
Preoperative and Postoperative Nevanac 0.1% Compared to Acular LS for the Treatment of Ocular Inflammation Associated With Cataract Surgery
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 267
- 试验地点
- 2
- 主要终点
- Percentage of patients who are a clinical success at Day 14 postoperative visit (where a "clinical success" is defined as aqueous cells < grade 1 and aqueous flare = grade 0 at the current visit and all subsequent visits).
研究概览
简要总结
The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 10 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •planned cataract extraction with posterior chamber intraocular lens implantation
排除标准
- 未提供
结局指标
主要结局
Percentage of patients who are a clinical success at Day 14 postoperative visit (where a "clinical success" is defined as aqueous cells < grade 1 and aqueous flare = grade 0 at the current visit and all subsequent visits).
次要结局
- Percentage of patients who are clinically cured, clinical successes, treatment failure, clinically significant inflammation
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Nepafenac 0.3% Two StudyCataractNCT01318499Alcon Research1,342
已完成
3 期
Nepafenac Compared to Placebo for Ocular Pain and InflammationCataractNCT01426854Alcon Research260
撤回
3 期
Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain after Cataract Surgeryocular inflammation and pain after cataract surgery10015919NL-OMON34348Alcon Laboratories120
进行中（未招募）
不适用
Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain after Cataract Surgery - Confirmatory Study Nepafenac 0.3%The Prevention and Treatment of Ocular Inflammation and Pain after Cataract SurgeryEUCTR2010-019507-28-SEAlcon Research, Ltd.2,000
进行中（未招募）
不适用
Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain after Cataract Surgery - Confirmatory Study Nepafenac 0.3%The prevention and treatment of ocular inflammation and pain after cataract surgery.MedDRA version: 9.1Level: LLTClassification code 10015943MedDRA version: 9.1Level: LLTClassification code 10015958EUCTR2010-019507-28-ITAlcon Research, Ltd.2,000